Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.34 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30525283 | 1.00 | NPC1 (0.53) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| SCHEMBL30525272 | 1.00 | NPC1 (0.53) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| Hydrochloric Acid SCHEMBL6053028 | 0.98 | NPC1 (0.56) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| SCHEMBL28183068 | 0.98 | NPC1 (0.51) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| SCHEMBL6053120 | 0.98 | NPC1 (0.51) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| SCHEMBL2003422 | 0.84 | NPC1 (0.47) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| SCHEMBL2003424 | 0.84 | NPC1 (0.47) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| SCHEMBL4430006 | 0.84 | NPC1 (0.47) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| Hydrochloric Acid SCHEMBL6053050 | 0.83 | NPC1 (0.50) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 | |
| Potassium Ion SCHEMBL6053118 | 0.83 | NPC1 (0.46) | NPC1HPGDRAB9ASMN1; SMN2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101563351-A | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-10-21 | — | — | CN | claimed |
| WO-2025085474-A1 | 5-OXO-4,5-DIHYDROIMIDAZO[1,5-A]QUINAZOLINE COMPOUNDS AS PI3K[ALPHA] INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20240398813-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-12-05 | — | — | US | disclosed |
| US-11932609-B1 | Substituted 1,4-dihydropyrimidines as antitubercular agents | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11912683-B1 | (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones as antitubercular agents | King Faisal University (SA) | 2024-02-27 | — | — | US | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023113114-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | 광주과학기술원 | 2023-06-22 | — | — | WO | disclosed |
| CN-116082360-A | Polycyclic compounds as SOS1 inhibitors | 昆药集团股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-102076689-A | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES SRL | 2011-05-25 | — | — | CN | disclosed |
| EP-2125822-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-12-02 | — | — | EP | disclosed |
| CN-101563351-A | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-10-21 | — | — | CN | disclosed |
| CN-101506214-A | Pyrazoloquinazolinones as PARP inhibitors | ABBOTT LAB (US) | 2009-08-12 | — | — | CN | disclosed |
| CN-101355936-A | Combinations comprising a CDK inhibitor and a growth factor antibody or an anti-mitotic agent | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-01-28 | — | — | CN | disclosed |
| EP-1846410-B1 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008074788-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
| CN-1826343-A | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | PHARMACIA ITALIA SPA (IT) | 2006-08-30 | — | — | CN | disclosed |
| EP-1636236-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104007-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398813-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | KCNK5, KCNAB1, KCNQ5 | NPC1 3354/4885HPGD 418/4885RAB9A 1513/4885 |
| US-11912683-B1 | (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones as antitubercular agents | TPMT, TBKBP1, MRM1 | NPC1 1500/4885HPGD 627/4885RAB9A 3830/4885 |
| US-11932609-B1 | Substituted 1,4-dihydropyrimidines as antitubercular agents | DPYD, DUT, TYMP | NPC1 1729/4885HPGD 421/4885RAB9A 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.